TY - JOUR AU - Y.V.Botsiurko, PY - 2022/12/28 Y2 - 2024/03/29 TI - MODERN HYPOLIPIDEMIC THERAPY (LITERATURE REVIEW) JF - PRECARPATHIAN BULLETIN OF THE SHEVCHENKO SCIENTIFIC SOCIETY Pulse JA - pulse VL - IS - 18 (66) SE - Статті DO - 10.21802/2304-7437-2022-18(66)-120-125 UR - https://pvntsh.nung.edu.ua/index.php/pulse/article/view/1854 SP - 120-125 AB - <p><em>Statins are highly effective drugs for the prevention and treatment of atherosclerotic cardiovascular diseases. With prolonged use, they can reduce cardiovascular risk by reducing the cholesterol content of low-density blood lipoproteins (LDL-C). However, even with a combination of a high-dose regimen of statin therapy with the use of ezetimib, it is not always possible to achieve the targets of LDL-C according to modern recommendations. Thus, there is an unmet clinical need for new lipid-lowering drugs that can lower cholesterol levels of low-density lipoproteins and other atherogenic lipoproteins. Over the past decade, a number of new drugs have been developed to treat dyslipidemia, which is reflected in this review.</em></p><p><strong><em>Key words: </em></strong><em>LDL cholesterol, statins, inclisiran, PCSK9 inhibitors, bempedoic acid.</em></p> ER -